(Q44533626)

3 December 2017

title

Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines (English)

1 reference

malignant pleural mesothelioma

3 December 2017

main subject

1 reference

Alessandra de Cupis

1

1 reference

3 December 2017

Claudia Semino

2

1 reference

3 December 2017

Paolo Pirani

3

1 reference

3 December 2017

Maura Loprevite

4

1 reference

3 December 2017

Andrea Ardizzoni

5

1 reference

3 December 2017

Roberto E Favoni

6

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

European Journal of Pharmacology

3 December 2017

published in

1 reference

3 December 2017

volume

473

1 reference

3 December 2017

issue

2-3

1 reference

3 December 2017

page(s)

83-95

1 reference

Current approach to malignant mesothelioma of the pleura

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Chemosensitivity and cytokine sensitivity of malignant mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

The epidemiology of mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Simian virus-40 large-T antigen binds p53 in human mesotheliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

The pathogenesis of asbestos-associated diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Features of apoptotic cells measured by flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Role of oxygen derivatives in the cytotoxicity and DNA damage produced by asbestos on rat pleural mesothelial cells in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

The emerging role of antifolates in the treatment of malignant pleural mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

The taxoids: paclitaxel and docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Long crocidolite asbestos fibers cause polyploidy by sterically blocking cytokinesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Malignant pleural mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

The role of gemcitabine in the treatment of malignant mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Multiplicity generates diversity in the retinoic acid signalling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Rapid activation of PDGF-A and -B expression at sites of lung injury in asbestos-exposed rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Retinoids and apoptosis: implications for cancer chemoprevention and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Chemotherapy in malignant pleural mesothelioma. A review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

The European mesothelioma epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Malignant mesothelioma: options for management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Current therapy for malignant mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

Induction of metaphase and anaphase/telophase abnormalities by asbestos fibers in rat pleural mesothelial cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901907-1

10.1016/S0014-2999(03)01907-1

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference